The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

Inclusion Criteria: 1. males or females, aged 18-45. 2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP\<140mmHg; 50mmHg ≤DBP\<90mmHg and 50 ≤ HR \<110 beats / min. 3. body mass index (BMI) between 18 to 28. 4. Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters. Exclusion Criteria: 1. males or females, aged 18-45. 2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP\<140mmHg; 50mmHg ≤DBP\<90mmHg and 50 ≤ HR \<110 beats / min. 3. body mass index (BMI) between 18 to 28. 4. Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters. Exclusion Criteria: 1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin \> 1X ULN during screening/baseline. 2. Serum creatinine\> 1X ULN during screening/baseline. 3. Abnormal coagulation function. 4. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs. 5. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening. 6. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration. 7. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive. 8.3 months prior to screening involved in any drug or medical device clinical studies or within 5 half-life of drugs before screening. 9.Female subjects who did not receive contraception at least 30 days before administration.